Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
Bausch & Lomb Corp CEO and Chairman Brent L. Saunders reported a tax-related share disposition. On February 23, 2026, 65,444 common shares at $17.99 per share were withheld to cover tax obligations upon vesting of restricted share units. After this withholding, Saunders beneficially owned 671,481 common shares directly.
Bausch & Lomb director Steven H. Collis reported two transactions in common shares. He made an open-market purchase of 15,000 shares at a weighted average price of $17.81 per share, increasing his direct holdings. He also received 4,491 matching restricted share units (MRSUs) granted under the company’s matching share program, tied to this purchase. One-third of these MRSUs will vest on each of the first, second, and third anniversaries of the grant, subject to his continued service. Following these transactions, he directly owned 24,746 common shares.
Bausch & Lomb director Russel C. Robertson increased his stake in the company through both a purchase and an equity award. He bought 4,400 common shares in an open-market transaction at $17.90 per share. On the same date, he also acquired 4,400 matching restricted share units at no cost under the company’s matching share program.
Following these transactions, his direct holdings rose to 76,807 common shares. The matching restricted share units will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as he continues to serve, except in limited circumstances.
Bausch & Lomb Corp director Karen Ling reported new purchases and awards of common shares. On February 19, 2026, she made an open-market purchase of 4,000 common shares at a weighted average price of $17.742 per share, with individual trades ranging from $17.71 to $17.75. She also acquired 4,000 matching restricted share units in connection with this purchase under the company’s matching share program, which vest in three equal annual installments starting one year after the grant date, subject to continued service.
Bausch & Lomb Corp reported that director Steven H. Collis acquired 5,255 common shares through an annual grant of restricted share units (RSUs) for non-employee directors. The RSUs were granted at no cash cost and are scheduled to vest immediately before the company’s next annual shareholder meeting.
Bausch & Lomb Corp director Alfonso Eduardo reported acquiring 5,255 common shares through an annual grant of restricted share units under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
The RSUs will be settled in common shares and are scheduled to vest immediately prior to the next annual meeting of shareholders.
Bausch & Lomb Corp director Russel C. Robertson acquired 1,451 restricted share units on common shares through a grant. The award was valued at $17.65 per share and increased his directly held position to 68,007 common shares, aligning his compensation partly with shareholder value.
Bausch & Lomb Corp director John Paulson received an equity grant of 1,239 restricted share units on common shares at a reference price of $17.65 per share. These units each represent a contingent right to receive one common share with no par value.
Following this grant, Paulson directly holds 72,606 common shares of Bausch & Lomb Corp. This transaction is reported as a grant, award, or other acquisition rather than an open-market purchase.
Bausch & Lomb Corp executive Frederick Munsch, SVP, Controller and CAO, reported acquiring 12,498 common shares at a price of $0.00 per share. These shares relate to performance stock units granted on March 1, 2023 that satisfied performance conditions as of February 18, 2026.
The earned PSUs will vest on March 1, 2026, generally contingent on Munsch’s continued employment through that date. Following this award, his directly held stake increased to 90,231 common shares.
Bonnefoy Luc reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp President, Surgical, Luc Bonnefoy reported an equity award involving 10,202 common shares of the company. These shares relate to performance stock units granted on March 1, 2023 that met their performance conditions as of February 18, 2026. The earned units are scheduled to vest on March 1, 2026, generally conditioned on his continued employment, bringing his reported direct holdings to 87,564 common shares.